Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00380211 · ClinicalTrials.gov registry record · Phase 3
Safety and Immunogenicity of FluLaval™ TR and Fluarix® (Influenza Vaccines) in Young and Older Adults
A Phase 3 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 3
- Development phase
- 660
- Enrollment target
NCT00380211: Completed Phase 3 study, sponsored by GlaxoSmithKline.
NCT00380211 is a Phase 3 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 660 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (15% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00380211, a Phase 3 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 660 participants
- Enrollment target
Study Summary
The purpose of this trial is to describe the immunogenicity, the safety, and tolerability of FluLaval™ TR and Fluarix®, the latter serving as active comparator. The results will be compared to a standard immune response criteria, for both young and elderly populations.
Interventions
- BIOLOGICAL Fluarix
- BIOLOGICAL Influenza vaccine (A/H3N2, A/H1N1, and B strains)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 660 participants |
| Start Date | 2006-09 |
| Est. Completion | 2006-11 |
| Phase | Phase 3 |
What the finished NCT00380211 record still lists
NCT00380211 is an interventional study that assigns participants to a tested intervention. The registered 660 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (15% lower).
The record links to 0 conditions, and to 2 interventions - of which Fluarix is the first listed.
NCT00380211 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00380211 about?
NCT00380211 is a clinical study titled "Safety and Immunogenicity of FluLaval™ TR and Fluarix® (Influenza Vaccines) in Young and Older Adults". The purpose of this trial is to describe the immunogenicity, the safety, and tolerability of FluLaval™ TR and Fluarix®, the latter serving as active comparator. The results will be compared to a standard immune response criteria, for both young and elderly populations.
What is the current status of trial NCT00380211?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 660 participants. The study started on 2006-09. Estimated completion is 2006-11.
What interventions are being tested in trial NCT00380211?
The interventions under investigation include: Fluarix (BIOLOGICAL), Influenza vaccine (A/H3N2, A/H1N1, and B strains) (BIOLOGICAL).
Who is sponsoring clinical trial NCT00380211?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00380211's enrollment target sits among peer trials
660 556th of 2000 higher than 1,440 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01185132 · 660 participants · Phase 3
Intensity Modulated Radiotherapy (IMRT) vs. 3D-conformal Accelerated Partial Breast Irradiation (APBI) for Early Stage Breast Cancer After Lumpectomy
- NCT03346694 · 660 participants · NA
Reducing Surgical Site Infection Rates Using an Alternative Sternal Dressing
- NCT05407636 · 660 participants · Phase 3
Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD
- NCT05470205 · 660 participants · Phase 3
Noninvasive Subharmonic Aided Pressure Estimation of Portal Hypertension; Renewal
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia